Nephrotic Syndrome is the leading cause of kidney failure in children and the third leading cause for adults. It is rare. It is debilitating. It can affect children and adults of any age, gender or race. And although it is chronic and life threatening, there are very few approved treatments.
As a Nephrotic Syndrome patient, caregiver, friend or family member, you know the difficulties in finding treatments and a cure for NS and FSGS. NephCure has been working tirelessly, for almost 15 years, to build partnerships with pharmaceuticals, researchers and doctors who specialize in glomerular disease. We now have the right players on the team and our window of opportunity to get better treatments brought to market.
The time is NOW.
Allow us to introduce NephCure Accelerating Cures Institute, a creative partnership between NephCure Kidney International and the University of Michigan. The NephCure Accelerating Cures Institute is all about combating the obstacles that have made it impossible to provide new and better treatments and a cure. Using strategies from successful rare disease care networks combined with new programs that incorporate patient-reported data, the Accelerating Cures Institute is the first of its kind and the only such model in the kidney field.
The goals we will accomplish with NACI include:
- Implementing a globally accepted standard of care that is effective for all patients
- Creating strength in numbers by engaging a motivated patient community in the drug discovery process
- Finding better treatment options in a timely and efficient manner
- Moving towards finding a cure